Tissue Regeneration Therapeutics Inc. Cell-Based Bioweapon Defense Technology Presented at the 2014 International Society for Stem Cell Research Conference
Toronto, Canada, June 20th 2014: Tissue Regeneration Therapeutics Inc. (TRT) today announced that pre-clinical research utilizing its patented mesenchymal stromal/stem cell (MSC) technology TXP, was presented at the International Society for Stem Cell Research conference in Vancouver June 19th. Dr. Lorena R. …
Tissue Regeneration Therapeutics Inc. (TRT) and Héma-Québec enter a definitive licensing agreement for the first human clinical trial of TXP-1
Toronto, Canada, June 2nd 2014: Tissue Regeneration Therapeutics Inc. (TRT) today announced it has entered into a definitive licensing agreement with Héma-Québec for the use of its patented mesenchymal stromal cell (MSC) technology TXP-1 for use in a clinical trial for the …
Tissue Regeneration Therapeutics Inc. (TRT) raises $3.25 Million to accelerate the development of its Mesenchymal Cell therapeutics platform
Toronto, Canada, July 10th 2013: Tissue Regeneration Therapeutics Inc. (TRT) today announced it has entered into a structured royalty sale transaction with SWK Holdings Corporation. The transaction, valued at US$3.25 million, was based on the strength of two TRT technology licenses in …
Umbilical Cord Cells Outperform Bone Marrow Cells in Repairing Damaged Hearts
TORONTO, Ontario (13 November, 2012) – A study published this month by researchers at the University of Toronto and Toronto’s Princess Margaret Hospital has shown that cells derived from the umbilical cord, “Human Umbilical Cord PeriVascular Cells” (HUCPVCs), are more effective in …
Tissue Regeneration Therapeutics Grants Exclusive U.S. License for PeriVascular Umbilical Cord Stem Cell Technology to PerkinElmer’s ViaCord® Cord Blood Banking Business
The agreement includes a collaborative research initiative, which supports Tissue Regeneration Therapeutics’ international leadership in the field of mesenchymal stem cell technology. Toronto, ON (October 28, 2011) – J. E. Davies, President and CEO of Tissue Regeneration Therapeutics (TRT), announced today an …
Trendsetters: Canadian Company Leads Stem Cell Industry in Research and Development
TORONTO (June 14, 2011) – In the last year, two major US cord blood companies have made human umbilical cord mesenchymal tissue/cell storage available to the public. This is a particularly exciting development for Toronto-based Tissue Regeneration Therapeutics (TRT) who have been …
- 1
- 2
Lastest Posts
